




<https://arcagy.org>



# GINECO AT ASCO 2026

# 12 SCIENTIFIC CONTRIBUTIONS





<https://arcagy.org>



# FRIDAY 29TH

2:45 – 5:45pm – S100bc

## **GINECO-CHIR101 / CHRONO**

A randomized phase II trial of the chronology of surgery after neoadjuvant chemotherapy for ovarian cancer.

*Jean-Marc Classe*

## **ENGOT-ov72 / ROSELLA**

Overall survival subgroup analyses for prior taxane use in the phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72, APGOT-Ov10, LACOG-0223, and ANZGOG-2221/2023).

*Lucy Gilbert*



<https://arcagy.org>




# SATURDAY 30TH

8:00 – 9:30am – 450a

## **ENGOT-ov58 / GINECO-OV244b / TEDOVA**

The neo-epitope-based vaccine OSE2101 with or without pembrolizumab versus best supportive care as maintenance in platinum-sensitive recurrent ovarian cancer patients with controlled disease after platinum-based chemotherapy.

*Alexandra Leary*





<https://arcagy.org>



# POSTER SESSION

JUNE 1st 9:00–12:00PM Hall A

## **GINECO-OV133b / RegeNovar**

RegeNovar: A phase I/II study of ubamatamab plus carboplatin, paclitaxel, and bevacizumab as salvage therapy in ovarian cancer with poor response to first-line chemotherapy.

*Benoit You*

## **ENGOT-ov26 / PRIMA**

Efficacy prediction for progression-free survival (PFS) and overall survival (OS) by genomic instability score (GIS) cutoffs in patients (pts) with advanced ovarian cancer (aOC): Post hoc results from the phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial.

*Bradley J. Monk*





<https://arcagy.org>



# POSTER SESSION

JUNE 1st 9:00–12:00PM Hall A

## **Bluestar-Endometrial01**

Puxitatug samrotecan (AZD8205) vs chemotherapy in patients with B7-H4-selected advanced/metastatic endometrial cancer: The phase 3 randomized Bluestar-Endometrial01 (BE01)/GOG-3110/ENGOT-EN28 trial.

*Stephanie Gaillard*

## **ENGOT-ov97 / FRAMework-01**

FRAMework-01: A two-part phase 3 study of sofetabart mipitecan versus chemotherapy or mirvetuximab soravtansine in platinum-resistant ovarian cancer (PROC), and sofetabart mipitecan plus bevacizumab versus platinum-based chemotherapy plus bevacizumab in platinum-sensitive ovarian cancer (PSOC).

*Bhavana Pothuri*



<https://arcagy.org>



# POSTER SESSION

JUNE 1st 9:00–12:00PM Hall A

## **REJOICE–Ovarian01**

REJOICE–Ovarian01: Phase 3 part of a phase 2/3 study evaluating raludotatug deruxtecan (R-DXd) versus treatment of physician's choice in patients with platinum-resistant ovarian cancer.

*Debra L. Richardson*

## **ENGOT–en31 / RAINFOL–03**

A global, phase 3, open-label, randomized study of rinatabart sesutecan (Rina-S) vs investigator's choice of chemotherapy in patients with endometrial cancer after platinum-based chemotherapy and programmed death-ligand 1 inhibition.

*Noelle Cloven*

## **ENGOT–ov96 / RAINFOL–04**

A phase 3, open-label, randomized study of rinatabart sesutecan (Rina-S) plus standard of care (SOC) vs SOC as maintenance treatment after second-line platinum-based chemotherapy in patients with recurrent platinum-sensitive ovarian cancer.

*Toon Van Gorp*



<https://arcagy.org>



# POSTER SESSION

JUNE 1st 9:00–12:00PM Hall A

## **ENGOT-ov84/ Trofuse-022**

Part 2: A phase 3 study of maintenance therapy with sacituzumab tirumotecan ± bevacizumab vs standard of care following second-line platinum-based doublet chemotherapy for platinum-sensitive recurrent ovarian cancer.

*Thomas J. Herzog*

## **ENGOT-cx22/ Trofuse-036**

A 2-part, phase 3, randomized study of sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) ± bevacizumab (bev) vs standard of care (SoC) as first-line maintenance therapy for PD-L1-positive cervical cancer.

*Brian M. Slomovitz*





<https://arcagy.org>



# SEE YOU AT ASCO 2026!

